Dhg Pharmaceutical Joint-Stock Co banner
D

Dhg Pharmaceutical Joint-Stock Co
VN:DHG

Watchlist Manager
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Watchlist
Price: 100 100 VND 0.3%
Market Cap: ₫13.1T

Relative Value

The Relative Value of one DHG stock under the Base Case scenario is 101 447.06 VND. Compared to the current market price of 100 100 VND, Dhg Pharmaceutical Joint-Stock Co is Undervalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DHG Relative Value
Base Case
101 447.06 VND
Undervaluation 1%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Multiples Across Competitors

DHG Competitors Multiples
Dhg Pharmaceutical Joint-Stock Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
13.1T VND 2.5 15.1 9.9 11.1
US
Eli Lilly and Co
NYSE:LLY
853.2B USD 13.1 41.3 27.9 29.8
US
Johnson & Johnson
NYSE:JNJ
566.5B USD 6 21.1 14.7 18.1
CH
Roche Holding AG
SIX:ROG
243.3B CHF 3.9 18.8 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
213.1B GBP 4.9 28 15.6 22
US
Merck & Co Inc
NYSE:MRK
288B USD 4.4 15.8 9.8 11.9
CH
Novartis AG
SIX:NOVN
222.8B CHF 5.1 20.7 12.8 16.5
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
153.3B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.5B USD 2.4 16.4 7 8.6
P/E Multiple
Earnings Growth PEG
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average P/E: 20.7
15.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.8
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBITDA: 45.4
9.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.6
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.8
3%
3.3
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett